Dr. Ronald Gingerich, Founder of Linco Diagnostic Services Inc., and Linco Research Inc. have over 30 years of immunoassay development experience. While employed for over 20 years at Washington University School of Medicine, St. Louis, Mo., Dr. Gingerich held positions as a research instructor, assistant professor, Associate Director, and then Director of the Radioimmunoassay Facility.

He currently serves as CEO/CSO of Linco Research Inc. and CEO/President of Linco Diagnostic Services Inc. . Dr. Gingerich is an active member of Professional societies in the science industry such as the American Diabetes Association, American Association of Lab Animal Science, American Association for Clinical Chemistry and the American Association of Pharmaceutic Scientist. Dr. Gingerich has authored over 100 publications and holds 2 patents.

Dr. Bowsher brings 30 years of pharmaceutical industry experience in bioanalytical method development from the Lilly Research Laboratories, a division of Eli Lilly and Company. His areas of expertise include the development, validation, and application of immunoassays for the quantitative determination of biotechnology products, conventional small molecule drugs, novel biomarkers, and anti-drug antibodies. He has published extensively in the area of analytical validation of immunoassays.

In the year 2000, he founded the AAPS Ligand Binding Assay Bioanalytical Focus Group to create a forum to address issues and provide education for the development and validation of ligand binding assays. Dr. Bowsher has authored nearly 200 publications, including 2 patents, and is a member of numerous professional societies, including ASPET, AACC, AAPS, AAAS, and the Endocrine Society.

Currently, he serves as the Chair-Elect of the AAPS Biotechnology Section and is an Adjunct Professor in the Dept. of Biochemistry and Molecular Biochemistry at Indiana University School of Medicine.

Dr. Thomas Cole brings to LINCO Diagnostics Services, Inc (LDS) more than 20 years of experience in the laboratory support of clinical trials for the pharmaceutical industry. At LDS, Dr. Cole will serve as Vice President of the Clinical Trials Services (CTS) Division where he will develop and direct high-quality analytical, logistical, and data handling support for multi-center clinical trials worldwide.

Dr. Cole developed the Core Laboratory for Clinical Studies at Washington University School of Medicine and served as its director for 20 years managing more than 70 clinical trials, prior to joining LDS. In addition to holding a faculty position of Research Professor of Biochemistry in Medicine at Washington University, he also served as director of the CDC-sponsored Cholesterol Reference Method Laboratory Network (CRMLN) laboratory and of the Secondary Reference Laboratory #4 of the National Glycohemoglobin Standardization Program.

Dr. Cole received his Ph.D. degree in pharmacology from the University of Missouri-Columbia and completed postdoctoral training programs in lipoprotein metabolism and in clinical chemistry at Washington University. He holds certification by the American Board for Clinical Chemistry and serves on its Board of Directors. He is active in the American Association for Clinical Chemistry having held a variety of elected and appointed positions. He is also a Fellow of the National Academy of Clinical Biochemistry and of the American Heart Association.

Dr. Cole has authored over 50 peer-reviewed publications and numerous book chapters on lipoprotein metabolism, assay development, and the performance of successful clinical trials and has served as a reviewer of many scientific journals.